Bourgeon Capital Management LLC Takes Position in Akero Therapeutics, Inc. $AKRO
Corient Private Wealth LLC Takes $3.93 Million Position in Akero Therapeutics, Inc. $AKRO
Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO
Novo Nordisk has completed its acquisition of Akero Therapeutics
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
My Top 3 Pharma Stocks
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
Akero Therapeutics soars after Novo Nordisk set for $5.2B cash acquisition
Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX
Top Stock Movers Now: Delta Air Lines, PepsiCo, Akero Therapeutics, and More
Shareholder Alert: The Ademi Firm investigates whether Akero Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
Akero Therapeutics Stock Surges on Novo Nordisk Buyout
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
Novo Nordisk acquires Akero Therapeutics and its promising liver therapy for up to $5.2B
AKRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akero Therapeutics, Inc. Is Fair to Shareholders
Akero Therapeutics Stock Soars on Novo Nordisk Deal.
Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion
Novo Nordisk buys Akero Therapeutics in the US
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
5 Biotech Stocks Worth Adding to Your Portfolio Now
Akero Therapeutics, Inc. (AKRO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?
Akero (AKRO) Q2 Loss Narrows 6%
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect
Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments